3 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
To assess safety and efficacy of AMX0035 for treatment of ALS.
Approved WMOCompleted
Primary objective is to assess in vivo neuroinflammation quantitatively in patients with sepsis. Secondary objective is to study whether differences in in vivo neuroinflammation are related to long term cognitive outcomes.